Flu vaccine study aims to unlock Age-Related immune secrets
NCT ID NCT04101838
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how four different FDA-approved flu vaccines affect the immune system in 50 adults aged 18-50 and 65-80. Researchers will measure antibody levels and memory B cells to see how age and past vaccination history influence the body's response. The goal is to understand why older adults often have weaker flu protection and how to improve future vaccines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inactivated seasonal influenza vaccines (Fluzone, Flucelvax, Fluzone High-Dose, Fluad)
- What this could lead to
- If successful, this study could help design better flu vaccines tailored to different age groups, potentially improving protection for older adults.
- What could go wrong
- This is an observational study of immune responses, not a test of new treatments. Results may not lead to immediate changes in vaccine recommendations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts